Gohealth Inc GOCO.OQ GOCO.O is expected to show a rise in quarterly revenue when it reports results on May 7 (estimated) for the period ending March 31 2025
The Chicago Illinois-based company is expected to report a 18.6% increase in revenue to $220.153 million from $185.6 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
LSEG's mean analyst estimate for Gohealth Inc is for a loss of 29 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Gohealth Inc is $23.00, above its last closing price of $8.81.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | 1.30 | 1.16 | 2.19 | Beat | 88.3 |
Sep. 30 2024 | -3.29 | -3.19 | 0.46 | Beat | 114.4 |
Jun. 30 2024 | -2.36 | -2.47 | -2.70 | Missed | -9.2 |
Mar. 31 2024 | -0.96 | -0.95 | -1.04 | Missed | -9.1 |
Dec. 31 2023 | 2.74 | 2.73 | -0.22 | Missed | -108.1 |
Sep. 30 2023 | -2.90 | -2.90 | -2.61 | Beat | 10 |
Jun. 30 2023 | -2.33 | -2.92 | -3.27 | Missed | -12.1 |
Mar. 31 2023 | -1.93 | -1.96 | -1.12 | Beat | 42.8 |
This summary was machine generated May 5 at 12:48 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。